Summary of Recommendation Statements.

Chapter 1: Assessment of lipid status in adults with CKD

1.1: In adults with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (

1.2: In adults with CKD (including those treated with chronic dialysis or kidney transplantation), follow-up measurement of lipid levels is not required for the majority of patients. (

Chapter 2: Pharmacological cholesterol-lowering treatment in adults

2.1.1: In adults aged ≥50 years with eGFR<60 ml/min/1.73 m

2.1.2: In adults aged ≥50 years with CKD and eGFR≥60 ml/min/1.73 m

2.2: In adults aged 18–49 years with CKD but not treated with chronic dialysis or kidney transplantation, we suggest statin treatment in people with one or more of the following (

known coronary disease (myocardial infarction or coronary revascularization)

diabetes mellitus

prior ischemic stroke

estimated 10-year incidence of coronary death or non-fatal myocardial infarction >10%

2.3.1: In adults with dialysis-dependent CKD, we suggest that statins or statin/ezetimibe combination not be initiated. (

2.3.2: In patients already receiving statins or statin/ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (

2.4: In adult kidney transplant recipients, we suggest treatment with a statin. (

Chapter 3: Assessment of lipid status in children with CKD

3.1: In children with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (

3.2: In children with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest annual follow-up measurement of fasting lipid levels. (

Chapter 4: Pharmacological cholesterol-lowering treatment in children

4.1: In children less than 18 years of age with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest that statins or statin/ezetimibe combination not be initiated. (

Chapter 5: Triglyceride-lowering treatment in adults

5.1: In adults with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. (

Chapter 6: Triglyceride-lowering treatment in children

6.1: In children with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. (

Quick summary of the KDIGO recommendations for lipid-lowering treatment in adults with CKD